Multicentre Evaluation of Commercial Kit Methods: Plasminogen Activator Inhibitor Activity

Summary

In order to study the analytical performance of different commercial kits for determination of plasminogen activator inhibitor (PAI) activity we distributed eight selected split samples to 11 European laboratories experienced with haemostasis testing. Three different laboratories were involved in the production of data from each of the commercial kits tested. A considerable variation of PAI activity results reported from the laboratories testing the same commercial kits was observed. The range of reported results could in individual samples exceed the median value indicating an interlaboratory variation of more than 100%.

When we harmonized the results reported from different kits in different laboratories by means of an international standard from National Institute for Biological Standards and Control (NIBSC) we still observed that the results produced by some kits deviated systematically from results produced by other kits. Also, the harmonized results were used to estimate the overall coefficient of variation (CV) of PAI activity determined in various laboratories by different kits. We observed an inverse correlation between the PAI activity level and the CV with a CV of about 10Q% for low PAI activity levels and a CV of about 16% for high PAI activity levels. The high imprecision of the kits in the low concentration range of PAI activity indicates that unspecific factors in plasma may interfere with determination of active PAI. This was confirmed by the evaluation of the results from one of the plasma samples, which was PAI-1 depleted. The laboratories involved in the testing reported for this sample a mean value of 6.1 IU/ml.

In conclusion, the currently available kits for determination of PAI activity are not accurate for measurement of PAI-1 in plasma, and the kits give imprecise results particularly at low activity levels.

• References

• 1 Hamsten A, Wiman B, de FaireU, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-1563
• 2 Paramo J, Colucci M, Collen D. Plasminogen activator inhibitor in the blood or patients with coronary artery disease. Br Med J 1985; 291: 573-574
• 3 Hamsten A, Blombäck M, Wiman B, Svensson J, Szamosi A, de FaireU, Mettinger L. Haemostatic function in myocardial infarction. Br Heart J 1986; 55: 058-066
• 4 Hamsten A, de FaireU, Walldius G. et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 003-009
• 5 Metha J, Metha P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987; 9: 263-268
• 6 Nilsson TK, Johnson O. The extrinsic fibrinolytic system in survivors of myocardial infarction. Thromb Res 1987; 48: 621-630
• 7 Verheugt FWA, ten CateJW, Sturk A. et al. Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries. Am J Cardiol 1987; 59: 1075-1079
• 8 Aznar J, Estelles A, Tormo G, Sapena P, Tormo V, Blanch S, España F. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 1988; 59: 535-541
• 9 Franus RB, Kawaniski D, Baruch T, Mahser P, Rahimtoola S, Feinstein DI. Impaired fibrinolysis in coronary artery disease. Am Heart J 1988; 115: 776-780
• 10 Korninger C, Jäger R, Huber K, Lechner K. Levels of plasminogen activator inhibitor in patients with angina pectoris. Klin Wochenschr 1988; SupplXII: 059-061
• 11 Olofsson BO, Dahlén G, Nilsson TK. Evidence for increased levels of plasminogen inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 1989; 10: 077-082
• 12 Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387
• 13 Chandler WL, Loo S-C, Nguyen SV, Schmer G, Stratton JR. Standardization of methods for measuring plasminogen activator inhibitor activity in human plasma. Clin Chem 1989; 35: 787-793
• 14 Kluft C, Jie AFH, Sprengers ED, Verheijen JH. Identification of a reversible inhibitor of plasminogen activators in human blood plasma. FEBS Lett 1985; 190: 315-318
• 15 Declerck PJ, De MolM, Alessi M-C. et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. J Biol Chem 1988; 263: 15454-15461
• 16 Alessi MC, Declerck PJ, De MolM, Nelles L, Collen D. Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1). Eur J Biochem 1988; 175: 531-540
• 17 Alessi M-C, Gaussem P, Juhan-Vague I, Aiach M, Musitelli J-J, Keuper JH. The determination of functional plasminogen activator inhibitors (PAI) based on the inhibition of urokinase: PAI normal range and circadian variations in healthy donors; comparison with other methods. Fibrinolysis 1990; 4: 001-005
• 18 Chmielewska J, Rånby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator inhibitor. Thromb Res 1983; 31: 427-436
• 19 Chmielewska J, Wiman B. Determination of tissue plasminogen activator and its fast inhibitor in plasma. Clin Chem 1986; 32: 482-485
• 20 Eriksson E, Rånby M, Gyzander E, Risberg B. Determination of plasminogen activator inhibitor in plasma using t-PA and a chromogenic single-point poly-D-lysine stimulated assay. Thromb Res 1988; 50: 091-101
• 21 Korninger C, Wagner O, Binder BR. Tissue plasminogen activator inhibitor in human plasma: development of a functional assay system and demonstration of a correlating Mr = 50,000 antiactivator. J Lab Clin Med 1985; 105: 718-724
• 22 Verheijen JH, Mullaart E, Chang GTG, Kluft C, Wijngaards G. A simple sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurement in plasma. Thromb Haemost 1982; 48: 266-269
• 23 Report from European Concerted Action on Thrombosis and Disabilities. The impact of sequential quality assessment exercises on laboratory performance: the multicentre ECAT angina pectoris study. Thromb Haemost 1991; 65: 149-52
• 24 Deming SN. Proficiency testing of clinical chemistry: the role of the reference laboratory. Clin Chem 1991; 37: 483
• 25 National Committee for Clinical Laboratory Standards. Development of Reference Methods for use in clinical chemistry for the National Reference system in clinical chemistry; tentative guidelines. NCCLS Document NRSCC 2-T Villanova: PA. NCCLS; 1984
• 26 Jespersen J. Gaps between the present assay practice in haemostasis and clinical chemistry laboratories. Fibrinolysis 1990; 4 (Suppl. 02) 118-120